Summit Therapeutics Share Discussion Threads

[abergele] 11/9/2017 12:19

I was on the verge for 1000 an hour back
the phone went,distracted me,
and this rns out of the blue,wowwwww,,
blew my 1000 @ £2.13 right away,, so took 500 @£2.40

[joeblogg2] 11/9/2017 12:19

This is truly amazing news. This will re-rate for many days to come!!!

[mirabeau] 11/9/2017 12:14

Go on my son!

[football] 11/9/2017 12:10

Roll on 2.30pm when the USA opens up

[waterloo01] 11/9/2017 12:04

Bloody hell, out of the blue!

[football] 11/9/2017 12:01

That will do nicely thank you

[hugus maximus] 08/9/2017 17:19

I know many of us are very optimistic about the value of Summits DMD work but find it difficult to quantify quite what the market cap might one day be. So an interesting post about Sarpeta (see below) that is very encouraging when you refer it's detail to the outlook for Summit. It explains how they are now advancing on further Exon skipping work that may help a further 8% of boys (in addition to their current 13% ... making a maximum of 21% of the DMD population that Sarepta could potentially help ... as opposed to Summit's potential 100%)

Then whilst comparing the above, there seems to be much speculation about Sarepta's potential for acquisition:

"As time passes and risk is reduced, the price tag for potential acquirers continues to move upward ... I'd say any deal at this point would conservatively start a share price of no less than $80,"

(EDIT - THAT WOULD MEAN THE SARPETA DMD WORK THEN PRESENTS A COMPANY MARKET CAP OF APPROX $4.5 billion)

"... with such a price target still achievable simply by continuing to execute on the commercial side while progressing the DMD pipeline through the clinic. Recent price targets set by Oppenheimer ($76), Credit Suisse ($81), Nomura ($84) and Needham ($75) suggest I'm not too far off."

Clearly this writer is a fan of Sarepta, but still an interesting measure of potential for work in the DMD field. I know Glyn acknowledged, whilst chatting at the last AGM, Summit will also be very ripe for the pickings if DMD P2 results start to show something positive. The article in full here:

[football] 08/9/2017 13:01

Lucky we have been up the last 2 days in the USA or were would the share price be

[hugus maximus] 07/9/2017 22:36

AIM might open a little higher tomorrow with a NASDAQ close up to $14.6 (= £2.23)

[hugus maximus] 06/9/2017 18:32

Well old Delboy has at least brought a smile at the end of a good day (AIM is closed in a better place ... we'll wait n see on the NASDAQ)

"Be millionaires by morning!"

[luminoso] 06/9/2017 18:10

I think Sarepta buying Summit ( at least all the DMD bit of SUMM ) and soon after being gobbled by a major is a possibility, as they do have the cash. They could make a killing if they time it right and I wonder if they have not already come to the conclusion that EZD is their best hope of making money in the DMD market.

[chrisatrdg] 06/9/2017 18:08

Spot on waterloo01.

Edit: NASDAQ is on a role currently up 7.47% at $14.25 (AIM £2.19).

Edit: NASDAQ close is up 4.97% at $13.92 (AIM £2.14) which supports AIM today.

[waterloo01] 06/9/2017 17:41

I'd put it right out your mind! One unknown poster has posted his own rumour, with a wink, wink, you heard it here first line and then says, don't say I told you or I'll be in trouble. All a bit Peckham for my taste.

Still Nasdaq back above $14, but that has more to do with SRPT news and the RDZ rns than Dellboy.

[hugus maximus] 06/9/2017 17:35

That was just what I was coming around to asking myself. i.e. "buy both?"

The new CEO at Sarepta is known to be a safe pair of hands in the event of such a thing and there's been speculation about Sarepta being taken on by a major for sometime.

Aside from some contentious questions about Eteplirsen success, Sarepta do have a pipeline of Exon skipping work way into the future and together with Summit's Utrophin research, perhaps there's potential for someone to take on the partnership as a one stop DMD shop ... ultimately one day helping the Beckers sufferers too ... that's quite some multi-billion dollar long term proposition.

Ok - just thinking .. that's all.

[chrisatrdg] 06/9/2017 17:15

I agree with waterloo01 SRPT's interest makes a Buy Out complicated almost unlikely unless as suggested both are Bought Out which I think is also unlikely.

I believe current share price reflects anticipation of a C-Diff deal following yesterdays RNS not that they are necessarily linked just perceived to be.

I just hope the share price now stays where it is & does not drift down as on all other occasions where there is a period of no news.

Good to see NASDAQ up again.Regards all.

[waterloo01] 06/9/2017 17:02

Unless they buy both?

[hugus maximus] 06/9/2017 16:59

Ah ha ... of course ... many thanks to the voice of reason!

[waterloo01] 06/9/2017 16:46

Don't buy into the buy out rumour. The deal with SRPT will act as poison pill.IMO

[hugus maximus] 06/9/2017 15:44

Afternoon Wildbunch - I've just checked out the source of this rumour - aka "LeKingEric" and he certainly called SXX & SML (which went from 0.75p to 3.5p a few weeks after a note he put on their thread saying there's a 4 bagger coming)

I guess there must constantly be chatter amongst the big pharmas as to which little fish they have their eye on ... but isn't a 5 bagger unlikely if there's some distant whiff of success been sniffed in the air for EZD in Q1? (Which is what would interest a big pharma)

Whatever ... some positive interest would be nice ;-/

EDIT - still some underpinning of the share price today.

[wildbunch] 06/9/2017 15:15

Some unsupported rumour on LSE that GSK or AZN might be interested in a t/o-suggest at 5 bagger price!

[hugus maximus] 06/9/2017 13:06

Sarepta keep on with their Exon skipping approach and have released results to prove that nothing dreadful happened in terms of tolerance to their newest drug Golodirsen in P1/2 test:



I think this is good for the financial stability of Sarepta, who we need to keep paying our bills!

[luminoso] 06/9/2017 08:11

Not really. They are waiting for the deal.

[dalcon01] 06/9/2017 06:54

Strange reaction Stateside?